196 related articles for article (PubMed ID: 30321870)
41. Clinical value of
Motegi SI; Fujiwara C; Sekiguchi A; Hara K; Yamaguchi K; Maeno T; Higuchi T; Hirasawa H; Kodaira S; Tomonaga H; Tsushima Y; Ishikawa O
J Dermatol; 2019 Mar; 46(3):213-218. PubMed ID: 30614031
[No Abstract] [Full Text] [Related]
42. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
[TBL] [Abstract][Full Text] [Related]
43. Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study.
Tsukada H; Tsukada J; Ochi T; Noguchi E; Okamoto T
Ann Nucl Med; 2022 Oct; 36(10):853-864. PubMed ID: 35819628
[TBL] [Abstract][Full Text] [Related]
44. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
[TBL] [Abstract][Full Text] [Related]
46. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
47. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
48. Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes.
Yang Q; Liu HY; Liu D; Song YQ
Asian Pac J Cancer Prev; 2015; 16(8):3229-32. PubMed ID: 25921124
[TBL] [Abstract][Full Text] [Related]
49. Reliability of
Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
[TBL] [Abstract][Full Text] [Related]
50. Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT.
Jeong YJ; Jung JW; Cho YY; Park SH; Oh HK; Kang S
Nucl Med Rev Cent East Eur; 2017; 20(1):32-38. PubMed ID: 28198519
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
52. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.
Wang CL; MacDonald LR; Rogers JV; Aravkin A; Haseley DR; Beatty JD
AJR Am J Roentgenol; 2011 Aug; 197(2):W247-55. PubMed ID: 21785049
[TBL] [Abstract][Full Text] [Related]
53. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
54. Relationships Between MRI Breast Imaging-Reporting and Data System (BI-RADS) Lexicon Descriptors and Breast Cancer Molecular Subtypes: Internal Enhancement is Associated with Luminal B Subtype.
Grimm LJ; Zhang J; Baker JA; Soo MS; Johnson KS; Mazurowski MA
Breast J; 2017 Sep; 23(5):579-582. PubMed ID: 28295860
[TBL] [Abstract][Full Text] [Related]
55. Correlation Between MRI and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer.
Ku YJ; Kim HH; Cha JH; Shin HJ; Baek SH; Lee HJ; Gong G
AJR Am J Roentgenol; 2016 Nov; 207(5):1146-1151. PubMed ID: 27556407
[TBL] [Abstract][Full Text] [Related]
56. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
57. Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.
Fujii T; Yanai K; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Hirakata T; Shirabe K
Anticancer Res; 2018 Aug; 38(8):4927-4931. PubMed ID: 30061271
[TBL] [Abstract][Full Text] [Related]
58. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
59. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
Jo JE; Kim JY; Lee SH; Kim S; Kang T
Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
[TBL] [Abstract][Full Text] [Related]
60. GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[
Capozza M; Anemone A; Dhakan C; Della Peruta M; Bracesco M; Zullino S; Villano D; Terreno E; Longo DL; Aime S
Mol Imaging Biol; 2022 Feb; 24(1):126-134. PubMed ID: 34383241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
